Table 1.

Twenty-four SNPs consistently associated with survival of NSCLC patients in the PLCO and HLCS GWAS datasets

SNP	Allelea	Gene	PLCO (n=1185)					HLCS (n=984)			Combined-analysis
			FDR	BFDP	EAF	HR (95% CI)b	P b	EAF	HR (95% CI)c	P c	P hetd	I 2	HR (95% CI)e	P e
rs1801701	C>T	APOB	0.27	0.34	0.09	0.75 (0.62–0.90)	0.002	0.09	0.81 (0.66–0.98)	0.032	0.592	0	0.78 (0.68–0.89)	0.0002
rs77105521	C>T	ABCG5	0.30	0.67	0.18	0.83 (0.73–0.95)	0.007	0.18	0.84 (0.72–0.97)	0.020	0.918	0	0.83 (0.76–0.92)	0.0003
rs76382861	G>A	RORA	0.29	0.47	0.15	0.81 (0.70–0.93)	0.002	0.13	0.81 (0.68–0.96)	0.017	0.998	0	0.81 (0.73–0.90)	0.0002
rs78023262	T>A	RORA	0.29	0.47	0.15	0.81 (0.70–0.93)	0.002	0.13	0.81 (0.68–0.96)	0.016	0.991	0	0.81 (0.73–0.90)	0.0002
rs35859010	C>T	CDH13	0.32	0.67	0.15	0.83 (0.72–0.95)	0.008	0.15	0.79 (0.65–0.96)	0.018	0.672	0	0.82 (0.73–0.91)	0.0004
rs1833970	T>A	CDH13	0.18	0.16	0.36	0.83 (0.74–0.92)	0.001	0.38	0.89 (0.79–1.00)	0.049	0.391	0	0.86 (0.79–0.93)	0.0001
rs2067861	C>T	CDH13	0.29	0.61	0.37	0.85 (0.77–0.95)	0.004	0.38	0.89 (0.79–1.00)	0.048	0.571	0	0.87 (0.80–0.94)	0.0003
rs9934609	C>T	CDH13	0.26	0.48	0.37	0.84 (0.75–0.94)	0.002	0.38	0.89 (0.79–1.00)	0.049	0.476	0	0.86 (0.80–0.94)	0.0004
rs9934700	C>T	CDH13	0.27	0.48	0.37	0.84 (0.75–0.94)	0.002	0.38	0.89 (0.79–0.99)	0.040	0.512	0	0.86 (0.80–0.93)	0.0003
rs6563943	G>A	CDH13	0.29	0.41	0.36	0.85 (0.76–0.94)	0.003	0.38	0.89 (0.79–1.00)	0.048	0.556	0	0.87 (0.80–0.94)	0.0004
rs72795378	G>A	CDH13	0.37	0.74	0.12	1.20 (1.04–1.38)	0.013	0.13	1.20 (1.03–1.40)	0.023	0.995	0	1.20 (1.08–1.33)	0.0006
rs17689520	C>G	CDH13	0.39	0.72	0.10	1.22 (1.04–1.42)	0.014	0.11	1.20 (1.00–1.42)	0.044	0.868	0	1.21 (1.08–1.36)	0.0014
rs60978336	C>A	CDH13	0.30	0.57	0.10	1.25 (1.06–1.46)	0.006	0.10	1.19 (1.00–1.42)	0.049	0.699	0	1.22 (1.09–1.38)	0.0008
rs12446784	A>G	CDH13	0.42	0.78	0.10	1.21 (1.03–1.41)	0.019	0.11	1.19 (1.00–1.42)	0.049	0.904	0	1.20 (1.07–1.35)	0.0020
rs72795399	A>G	CDH13	0.42	0.78	0.10	1.21 (1.03–1.41)	0.019	0.11	1.20 (1.00–1.43)	0.044	0.932	0	1.20 (1.07–1.35)	0.0019
rs11525693	C>G	CDH13	0.40	0.77	0.10	1.22 (1.04–1.43)	0.016	0.10	1.20 (1.01–1.43)	0.043	0.886	0	1.21 (1.08–1.36)	0.0014
rs254315	T>C	CDH13	0.29	0.67	0.15	1.21 (1.06–1.39)	0.006	0.15	1.19 (1.02–1.38)	0.029	0.844	0	1.20 (1.08–1.33)	0.0004
rs374476	A>G	CDH13	0.30	0.59	0.15	1.21 (1.06–1.38)	0.006	0.15	1.19 (1.02–1.39)	0.024	0.899	0	1.20 (1.09–1.33)	0.0003
rs425904	T>C	CDH13	0.41	0.78	0.20	1.16 (1.03–1.30)	0.017	0.21	1.15 (1.01–1.31)	0.039	0.917	0	1.16 (1.06–1.26)	0.0011
rs183436	A>C	ABCG1	0.31	0.72	0.32	0.86 (0.78–0.96)	0.007	0.31	0.88 (0.78–1.00)	0.046	0.734	0	0.87 (0.80–0.94)	0.0005
rs225390	G>A	ABCG1	0.29	0.72	0.33	0.86 (0.77–0.96)	0.006	0.33	0.87 (0.77–0.99)	0.029	0.854	0	0.87 (0.80–0.94)	0.0005
rs225395	C>T	ABCG1	0.29	0.61	0.34	0.85 (0.76–0.95)	0.003	0.34	0.88 (0.79–1.00)	0.043	0.637	0	0.87 (0.80–0.94)	0.0005
rs225398	C>G	ABCG1	0.29	0.56	0.34	0.86 (0.77–0.95)	0.005	0.35	0.88 (0.78–0.99)	0.038	0.768	0	0.87 (0.80–0.94)	0.0005
rs174699	T>C	COMT	0.18	0.13	0.05	1.45 (1.17–1.79)	0.001	0.05	1.30 (1.02–1.68)	0.037	0.527	0	1.39 (1.18–1.63)	0.0001

Abbreviations: SNP, single nucleotide polymorphism; NSCLC, non-small cell lung cancer; GWAS, genome-wide association study; PLCO, Prostate, Lung, Colorectal and Ovarian cancer screening trial; EAF, effect allele frequency; HR, hazards ratio; CI, confidence interval; FDR, false discovery rate; BFDP, Bayesian false discovery probability; HLCS, Harvard Lung Cancer Susceptibility.

^aReference>effect allele,

^bObtained from an additive genetic model with adjustment for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3, and PC4;

^cObtained from an additive genetic model with adjustment for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2, and PC3;

^dP _het: P value for heterogeneity by Cochrane’s Q test;

^eMeta-analysis in the fixed-effects model.